Information Provided By: 
Fly News Breaks for September 11, 2017
IPXL
Sep 11, 2017 | 07:44 EDT
Cantor Fitzgerald analyst Louise Chen raised her price target for Impax Laboratories to $25 from $20 citing expectations for multiple expansion. The specialty pharmaceutical company closed Friday up 5c to $21.10. The analyst, after speaking to management, believes the company's execution of its stated business objectives continues to meet or beat her expectations. Impax is an "interesting asset" in a consolidating industry, and its stock can go higher from here, Chen tells investors in a research note. She has an Overweight rating on the shares.
News For IPXL From the Last 2 Days
There are no results for your query IPXL
